Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

Author： Coltelli Luigi Allegrini Giacomo Orlandi Paola Giuntini Nicola Alìì Greta Fioravanti Anna Bona Eleonora Barletta Maria Teresa Fontanini Gabriella Tacca Mario Del Danesi Romano Falcone Alfredo Bocci Guido

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.8, 2009-08, pp. : 1225-1229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Germline pharmacogenetics of paclitaxel for cancer treatment

By Hertz Daniel L

Pharmacogenomics, Vol. 14, Iss. 9, 2013-07 ,pp. : 1065-1084

Future Medicine

Access to resources Recommend Favorite

KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3862-3865

Blackwell Publishing

Access to resources Recommend Favorite

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

By Troiani Teresa Martinelli Erika Orditura Michele De Vita Ferdinando Ciardiello Fortunato Morgillo Floriana

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 949-959

Informa Healthcare

Access to resources Recommend Favorite

Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population

By Kjaer-Frifeldt Sanne Fredslund Rikke Lindebjerg Jan Hansen Torben Froestrup Spindler Karen-Lise Garm Jakobsen Anders

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 763-770

Future Medicine

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic

Current Medicinal Chemistry, Vol. 13, Iss. 16, 2006-07 ,pp. : 1845-1857

Bentham Science Publishers

Access to resources Recommend Favorite